CAR T-Cell Therapy Market Forecasted to Grow at a CAGR of More than 20% from 2023 to 2028 CAR T-cell therapy is a type of immunotherapy that uses genetically engineered T cells to fight cancer. T cells are a type of white blood cell that plays a role in the body's immune system. In CAR T-cell therapy, T cells are removed from the patient's body, genetically engineered to express a chimeric antigen receptor (CAR), and then returned to the patient. The CAR allows the T cells to recognize and kill cancer cells that express the same antigen. Get a Sample copy of Report@: https://www.pragmamarketresearch.com/reports/119618/global-car-t-cell-therapy-market-outlook/inquiry?UTM=PRohit CAR T-cell therapy has been shown to be effective in treating a variety of blood cancers, including leukemia, lymphoma, and multiple myeloma. It has also been shown to be effective in treating some solid tumors, such as colorectal cancer. The global CAR T-cell therapy market is projected to grow at a CAGR of more than 20% from 2023 to 2028. The growth of the market is being driven by the increasing prevalence of cancer, the rising demand for personalized cancer therapies, and the increasing number of clinical trials evaluating CAR T-cell therapy for the treatment of a variety of cancers. Get more information on the report@: https://www.pragmamarketresearch.com/reports/119618/global-car-t-cell-therapy-market-outlook?UTM=PRohit The key players in the global CAR T-cell therapy market include Autolus Therapeutics (U.K), CARsgen Therapeutics Co.Ltd. (U.K), Juno Therapeutics Inc. (Bristol-Myers Squibb Company), Sorrento Therapeutics Inc. (U.S)., bluebird bio-Inc. (U.S), CELGENE CORPORATION (U.S), Eureka Therapeutics Inc. (U.S), Avacta Life Sciences Ltd. (U.K), Celyad Oncology SA (Belgium), Fortress Biotech Inc (U.S.)., Gilead Sciences Inc. (U.S.), Novartis AG (Switzerland), Alaunos Therapeutics Inc (U.S.)., Poseida Therapeutics Inc. (U.S.), Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, Curocell, Inc., JW Therapeutics (Shanghai) Co., Ltd., Stempeutics Research PVT LTD, ACROBiosystems, Sangamo Therapeutics, Inc., Servier Laboratories, Noile-Immune Biotech, Inc., Miltenyi Biotec The market is segmented by application into leukemia, lymphoma, colorectal cancer, multiple myeloma, autoimmune disorders, and others. The leukemia segment is expected to be the largest segment of the market during the forecast period. This is due to the increasing incidence of leukemia and the high efficacy of CAR T-cell therapy in treating leukemia. Buy Full Report (Single User) @ https://www.pragmamarketresearch.com/buy/119618?type=su&UTM=PRohit The market is also segmented by type into Breyanzi, Yescarta, Abecma, Kymriah, Tecartus, and others. The Breyanzi segment is expected to be the largest segment of the market during the forecast period. This is due to the approval of Breyanzi by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy is a promising new treatment for cancer. It is still a relatively new therapy, and there are some risks associated with it. However, the potential benefits of CAR T-cell therapy are significant, and the market for this therapy is expected to grow rapidly in the coming years. Contact Us: Pragma Market Research, +1 425 230 0999 Sales@pragmamarketresearch.com

Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Market Report Presents an Overall Analysis, Development Trends, Driving Forces, Opportunities The global relapsed or refractory diffuse large B-cell lymphoma market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.2% in the forecasted period. The rise in the number of oncology procedures is anticipated to boost the growth of the relapsed or refractory diffuse large B-cell lymphoma market during the forecasted period. Get A Report Copy of this Market: https://wemarketresearch.com/reports/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-market/904/